Effects of photobiomodulation therapy for acute radiation dermatitis in patients with cancer: A systematic review and meta‑analysis of real-world evidence

• Published in: Radiotherapy and oncology Vol. 202; p. 110589
• Main Authors: Lin, Ying-Tong, Mou Tung, Kuang, Chiou, Jeng-Fong, Chen, Yen-Chao, Hou, Wen-Hsuan
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.01.2025
• Subjects: Acute radiation dermatitis; Cancer; Low-intensity laser; Low-level laser; Photobiomodulation therapy; Radiotherapy; CTCAE; RT; RCT; Gray; Photobiomodulation therapy; MASCC; CI; PRISMA; Radiotherapy; Acute radiation dermatitis; RD; ARD; Low-level laser; NCI; WALT; PBMT; RTOG; Low-intensity laser; Cancer
• ISSN: 0167-8140; 1879-0887; 1879-0887
• DOI: 10.1016/j.radonc.2024.110589

•Photobiomodulation therapy (PBMT) could benefit acute radiation dermatitis (ARD).•PBMT significantly reduces ARD severity in cancer patients receiving radiotherapy.•PBMT has beneficial effects on the prevention and treatment of higher-grade ARD.•PBMT benefits both breast cancer patients and head and neck cancer patients. To examine the effectiveness of photobiomodulation therapy (PBMT) for acute radiation dermatitis (ARD) in patients with cancer. PubMed, Embase, Cochrane Library, and CINAHL were searched for articles published between database inception until July 2024. Randomized controlled trials (RCTs) and non-RCTs examining the effects of PBMT against ARD in patients with cancer were included for analysis. A random-effects model was used to conduct meta-analyses and sensitivity analyses. Subgroup analyses were conducted for cancer types and PBMT goals (prevention or treatment of ARD) with stratification for different grades of ARD. Eight studies (five RCTs and three non-RCTs) were included in this meta-analysis. Compared with the control group, the PBMT group exhibited significantly lower ARD incidence at grades 2 and 3 (risk difference =  − 0.36, 95 % confidence interval =  − 0.53 to − 0.19, I2 = 85 %, P = < 0.00001). Subgroup analyses revealed that, compared with the control group, PBMT had a significant effect on both breast cancer and head and neck cancer. In addition, PBMT significantly reduced grades 2 and 3 ARD incidence in the PBMT group for both prevention and treatment subgroups. PBMT may have beneficial effects on the prevention and treatment of higher-grade ARD in patients with breast cancer and head and neck cancer. Nevertheless, the studies included in this meta-analysis exhibited high heterogeneity. Therefore, the results must be interpreted with caution.